Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Large Cell Neuroendocrine Carcinoma of the Lung
NCT06049966Phase 1Completed
- Sponsor
- Oncology Center of Biochemical Education and Research
- Start
- Nov 2019
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab in large cell neuroendocrine carcinoma of the lung (LCNEC) (2 arms), sponsored by Oncology Center of Biochemical Education and Research. Primary endpoints: Progression-Free Survival up to 70 months and Overall Survival up to 70 months. Started Nov 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
large cell neuroendocrine carcinoma of the lung (LCNEC)
Beyond the preview
Go deeper on NCT06049966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049966.